Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 102

Sort by

Sort Order Select

Journal Articles

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood (2024) 144 (19): 2033–2044.

https://doi.org/10.1182/blood.2024024756

Published: 2024

Includes: Supplemental data

Journal Articles

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Underwent Allogenic Stem Cell Transplantation (HSCT)

Blood (2023) 142 (Supplement 1): 4980.

https://doi.org/10.1182/blood-2023-186578

Published: 2023

Journal Articles

Association between BMI and Survival in Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia Treated with Intensive Chemotherapy

Erin Jay Feliciano, Tara Cronin, Pamela Jeannette Sung, Steven Green, Elizabeth A. Griffiths, James E Thompson, Eunice S Wang

Blood (2023) 142 (Supplement 1): 1476.

https://doi.org/10.1182/blood-2023-189070

Published: 2023

Journal Articles

Development of Oral Azacitidine with Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including CMML (Chronic Myelomonocytic Leukemia) By Targeting Pharmacokinetic AUC Equivalence Vs Subcutaneous Azacitidine

Guillermo Garcia-Manero, James McCloskey, Bart L. Scott, Elizabeth A. Griffiths, Bonnie Kiner-Strachan, Gail J. Roboz, Janelle Meyer, Winny Chan, Beloo Mirakhur, Yuri Sano, Aram Oganesian, Harold N. Keer, Michael R. Savona

Blood (2023) 142 (Supplement 1): 3245.

https://doi.org/10.1182/blood-2023-178024

Published: 2023

Journal Articles

Optimal Therapeutic Strategies in Relapsed/Refractory AML with Prior Exposure to Venetoclax Based Therapy

Sawyer Bawek, Prutha Patel, Katy Wang, Kristopher Attwood, Tara Cronin, Melissa Fos, Steven Green, Pamela Jeannette Sung, James E Thompson, Elizabeth A. Griffiths, Eunice S Wang, Amanda C. Przespolewski

Blood (2023) 142 (Supplement 1): 4271.

https://doi.org/10.1182/blood-2023-190790

Published: 2023

Journal Articles

Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial

Blood (2023) 142 (Supplement 1): 76.

https://doi.org/10.1182/blood-2023-188904

Published: 2023

Journal Articles

Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis

Blood (2023) 142 (Supplement 1): 4613.

https://doi.org/10.1182/blood-2023-178728

Published: 2023

Journal Articles

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

Blood (2023) 142 (Supplement 1): 4619.

https://doi.org/10.1182/blood-2023-188258

Published: 2023

Journal Articles

Evaluation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) with Missing Molecular Data

Blood (2023) 142 (Supplement 1): 4607.

https://doi.org/10.1182/blood-2023-187053

Published: 2023

Journal Articles

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Luca Lanino, Somedeb Ball, Jan Philipp Bewersdorf, Monia Marchetti, Giulia Maggioni, Erica Travaglino, Najla H Al Ali, Pierre Fenaux, Uwe Platzbecker, Valeria Santini, Maria Diez-Campelo, Avani M Singh, Akriti Gupta Jain, Luis E. Aguirre, Sara M. Tinsley-Vance, Zaker I. Schwabkey, Onyee Chan, Zhuoer Xie, Andrew M. Brunner, Andrew T. Kuykendall, John M. Bennett, Rena Buckstein, Rafael Bejar, Hetty E. Carraway, Amy E. DeZern, Elizabeth A. Griffiths, Stephanie Halene, Robert Hasserjian, Jeffrey Lancet, Alan F. List, Sanam Loghavi, Olatoyosi Odenike, Eric Padron, Mrinal M. Patnaik, Gail J. Roboz, Maximilian Stahl, Mikkael A. Sekeres, David Peter Steensma, Michael R. Savona, Justin Taylor, Mina Xu, Kendra Sweet, David A Sallman, Stephen D. Nimer, Christopher S. Hourigan, Andrew H. Wei, Elisabetta Sauta, Saverio D'Amico, Gianluca Asti, Gastone Castellani, Uma M. Borate, Guillermo Sanz, Fabio Efficace, Steven D. Gore, Tae Kon Kim, Naval Daver, Guillermo Garcia-Manero, María Rozman, Alberto Orfao, Sa A. Wang, M. Kathy Foucar, Ulrich Germing, Torsten Haferlach, Phillip Scheinberg, Yasushi Miyazaki, Marcelo Iastrebner, Austin Kulasekararaj, Thomas Cluzeau, Shahram Kordasti, Arjan A. van de Loosdrecht, Lionel Ades, Amer M. Zeidan, Rami S. Komrokji, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 998.

https://doi.org/10.1182/blood-2023-186580

Published: 2023

Journal Articles

Checkpoint Immunotherapy Is Associated with Preferential Activation of Tumor-Antigen Specific CD4 + T Cells in MDS

Elizabeth A. Griffiths, Pragya Srivastava, Eduardo Cortes Gomez, Junko Matsuzaki, Kunle Odunsi, Laura W Dillon, Devdeep Mukherjee, Christopher S. Hourigan, Jacqueline Peng, Shovik Bandyopadhyay, Kai Tan, Krista Belko, Amanda C. Przespolewski, Eunice S. Wang, Prashant Singh, Jianmin Wang, Michael J. Nemeth

Blood (2023) 142 (Supplement 1): 4602.

https://doi.org/10.1182/blood-2023-178756

Published: 2023

Journal Articles

Clinical Implications of TP53 Mutations/Allelic State in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Treated with Hypomethylating Agents (HMA)- a Multicenter, Retrospective Analysis from the Validate Database

Blood (2023) 142 (Supplement 1): 1002.

https://doi.org/10.1182/blood-2023-186875

Published: 2023

Journal Articles

Validation of the Composite Complete Response (cCR) Definitions in the International Working Group (IWG) 2023 Criteria in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Treated with Hypomethylating Agents (HMA) - a Large, Multicenter, Retrospective Analysis from the Validate Database

Blood (2023) 142 (Supplement 1): 324.

https://doi.org/10.1182/blood-2023-180299

Published: 2023

Journal Articles

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)

Blood (2023) 142 (Supplement 1): 3240.

https://doi.org/10.1182/blood-2023-186340

Published: 2023

Journal Articles

Antigen-Specific T-Cell Repertoire Responses Following COVID-19 Vaccination Are Intact in Majority of Patients with B-Cell Lymphoid Malignancies on Active Therapy

Shipra Goel, Elizabeth A. Griffiths, Brahm Segal, Michael Nemeth, Matthew J Cortese, Francisco J. Hernandez-Ilizaliturri, Barbara Banbury, Erika Schumacher, Pallawi Torka, Paola Ghione

Blood (2023) 142 (Supplement 1): 5714.

https://doi.org/10.1182/blood-2023-190914

Published: 2023

Journal Articles

Inotuzumab Ozogamicin + Blinatumumab +/- Rituximab + Mini-Hcvd Shows Improved Tolerability with Similar Efficacy Compared to E1910 in Treatment of Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia in Older Adults

Jordan Scott, Samantha Poblete, Jared Vega, Amanda C. Przespolewski, James E Thompson, Elizabeth A. Griffiths, Pamela Jeannette Sung, Steven Green, Han Yu, Michael Shenal, Eugene Przespolewski, Eunice S. Wang, Jeffrey Baron

Blood (2023) 142 (Supplement 1): 5891.

https://doi.org/10.1182/blood-2023-181332

Published: 2023

Journal Articles

Outcomes of Extramedullary Acute Myeloid Leukemia with Gemtuzumab Ozogamicin: Real-World Experience

Riya Patel, Khalid Shalaby, Charles Roche, Hassan Awada, Elizabeth A. Griffiths, James E Thompson, Steven Green, Pamela Jeannette Sung, Eunice S. Wang, Amanda C. Przespolewski

Blood (2023) 142 (Supplement 1): 5916.

https://doi.org/10.1182/blood-2023-185058

Published: 2023

Journal Articles

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Blood (2023) 141 (17): 2047–2061.

https://doi.org/10.1182/blood.2022018604

Published: 2023

Includes: Supplemental data

Journal Articles

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia

Amanda Przespolewski, Aaron D. Goldberg, Chetasi Talati, Salman Fazal, Pankit Vachhani, Srinivasa R. Sanikommu, Swapna Thota, Julian Waksal, Brian Ball, Christopher Famulare, Maximilian Stahl, Jeffrey Baron, Elizabeth A. Griffiths, James E. Thompson, Kendra Sweet, Eunice S. Wang

Blood (2023) 141 (12): 1489–1493.

https://doi.org/10.1182/blood.2022016678

Published: 2023

Includes: Supplemental data

Journal Articles

ASTX727-03: Phase 1 Study Evaluating Oral Decitabine/Cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients

Guillermo Garcia-Manero, Kimo Bachiashvili, Harshad Amin, Elie Traer, Daniel A. Pollyea, David A. Sallman, Aref Al-Kali, Larry D. Cripe, Jesus G Berdeja, Elizabeth A. Griffiths, Sanjay R Mohan, Yuri Sano, Aram Oganesian, Harold N. Keer, Abdulraheem Yacoub

Blood (2022) 140 (Supplement 1): 1112–1114.

https://doi.org/10.1182/blood-2022-156512

Published: 2022

NARROW

Risk prediction for clonal cytopenia: multicenter real-world evidence

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Underwent Allogenic Stem Cell Transplantation (HSCT)

Association between BMI and Survival in Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia Treated with Intensive Chemotherapy

Development of Oral Azacitidine with Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including CMML (Chronic Myelomonocytic Leukemia) By Targeting Pharmacokinetic AUC Equivalence Vs Subcutaneous Azacitidine

Optimal Therapeutic Strategies in Relapsed/Refractory AML with Prior Exposure to Venetoclax Based Therapy

Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial

Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

Evaluation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) with Missing Molecular Data

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Checkpoint Immunotherapy Is Associated with Preferential Activation of Tumor-Antigen Specific CD4 + T Cells in MDS

Clinical Implications of TP53 Mutations/Allelic State in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Treated with Hypomethylating Agents (HMA)- a Multicenter, Retrospective Analysis from the Validate Database

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)

Antigen-Specific T-Cell Repertoire Responses Following COVID-19 Vaccination Are Intact in Majority of Patients with B-Cell Lymphoid Malignancies on Active Therapy

Inotuzumab Ozogamicin + Blinatumumab +/- Rituximab + Mini-Hcvd Shows Improved Tolerability with Similar Efficacy Compared to E1910 in Treatment of Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia in Older Adults

Outcomes of Extramedullary Acute Myeloid Leukemia with Gemtuzumab Ozogamicin: Real-World Experience

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia

ASTX727-03: Phase 1 Study Evaluating Oral Decitabine/Cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only